.. Stratégie-thérapeutique-au-stade-Évolué, .95 I.1.3.2.2 Prise en charge des complications liées à l'évolution de la maladie97 ? Troubles du sommeil, Troubles tensionnels, vol.100, p.101

M. Traitement-non, .105 I.2.1 Traitement chirurgical, .108 I.2.2.2 L'ergothérapie

I. Les-thérapie-futures-et-les-nouvelles-voies-de-recherches and .. , 111 II.1 La stimulation magnétique transcrânienne111 II.2 La thérapie cellulaire111 II.2.1 Les greffes de cellules humaines foetales, ., p.111

G. La-thérapie, 112 II.4 Inhibition enzymatique : inhibition de la sirtuine 2, p.113

I. Résultats-de-l-'enquête and .. , 114 II.1 La population115 II.2 Le traitement, 117 II.2.2 Aspect général, p.135

L. , .. Parkinson-compliquée, .. , and .. , 136 II.3.2.1 Les fluctuations, ., p.145

. Conférence-de-consensus, La maladie de Parkinson : critères diagnostiques et thérapeutiques . Texte court, Rev Prat, vol.14, issue.497, pp.832-838, 2000.

J. Parkinson, R. Sherwood, N. , and J. , An essay on the shaking palsy, pp.1817-66

J. Costentin, La maladie de Parkinson et ses traitements, Impact Pharmacien, vol.38, pp.32-37, 1999.

G. Fénelon and . Maladie-de-parkinson, Prendre en charge toutes les dimensions de la maladie

L. Defebvre and . Maladie-de-parkinson, Epidémiologie et symptômes inauguraux, Le Quotidien du médecin, pp.8025-8035, 2006.

L. Médical, Paris : Larousse, p.32, 1219.

M. Latash, Bases neurophysiologiques du mouvement.-1e ed, 296p.-(Collection sciences et pratiques du sport), 2002.

G. Alexander, M. Delong, and P. Strick, Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex, Annual Review of Neuroscience, vol.9, issue.1, pp.357-381, 1986.
DOI : 10.1146/annurev.ne.09.030186.002041

M. Delong, Primate models of movements disorders of basal ganglia origin., Trends

D. Richard and O. D. Neurophysiologie, Motricité et grandes fonctions du système nerveux central, Paris : Dunod, vol.256, issue.2, 2000.

J. Mink and W. Tach, Basal ganglia motor control. III. Pallidal ablation: normal reaction time, muscle cocontraction, and slow movement, Journal of Neurophysiology, vol.65, issue.2, pp.330-351, 1991.
DOI : 10.1152/jn.1991.65.2.330

A. Graybiel, Neurotransmitters and neuromodulators in the basal ganglia. Trends

C. Gerfen, J. Mcginty, and W. Young, Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis, J Neurosci, vol.11, pp.1016-1031, 1991.

C. Gerfen, The neostriatal mosaic : multiple levels of compartmental organization

. Paris, Flammarion, Médecine-Sciences, 1985.

M. Ziegler and J. Bleton, La maladie de Parkinson et son traitement. 2 e éd

F. Zagnoli and F. Rouhart, Maladie de Parkinson. 2 e éd, Rueil Malmaison : Doin, p.209, 2006.

L. Peyrin and Y. Dalmaz, La sécrétion et l'inactivation périphérique des catécholamines

B. Scatton, Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease, Brain Research, vol.275, issue.2, pp.321-328, 1983.
DOI : 10.1016/0006-8993(83)90993-9

J. Yvette, Maladie de Parkinson : état des connaissances en 1999, Thèse de pharmacie, 1999.

C. Frederic, Maladie de Parkinson, traitements et stratégies

N. Sheehan and . La-maladie-de-parkinson, Certitudes et controverses pharmacothérapeutiques (première partie), Pharmactuel, vol.33, issue.2, pp.36-46, 2000.

G. Fénelon, Prise en charge des troubles psychiques dans la Maladie de Parkinson

Y. Hoehn and . Md, Parkinsonism: onset, progression, and mortality, Neurology, vol.17, issue.5, pp.427-442, 1967.
DOI : 10.1212/WNL.17.5.427

URL : http://www.neurology.org/content/17/5/427.full.pdf

A. Destee, Les stratégies du traitement antiparkinsonien, Rev Prat, vol.55, issue.7, pp.723-731, 2005.

D. Riley and A. Lang, The spectrum of levodopa-related fluctuations in Parkinson's disease, Neurology, vol.43, issue.8
DOI : 10.1212/WNL.43.8.1459

J. Flaherty, B. Gidal, L. Young, and M. Koda-kimble, Parkinson's disease The clinical use of drugs, 6 e ed, pp.1-16, 1995.

K. Grosset, F. Needleman, and G. Macphee, Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five-drug dose conversion table, Movement Disorders, vol.24, issue.11
DOI : 10.1017/S0317167100000068

P. Dorosz and . Antiparkinsoniens, In : Guide pratique des médicaments

J. Montastruc, O. Rascol, and J. Senard, Les médicaments antiparkinsoniens : bilan et nouvelles perspectives pharmacologiques, Médecine et hygiène, pp.1852-1860, 1990.

C. Olanow and W. Koller, An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines, Neurology, vol.50, issue.Issue 3, Supplement 3, pp.1-57, 1998.
DOI : 10.1212/WNL.50.3_Suppl_3.S1

K. Lange, Clinical Pharmacology of Dopamine Agonists in Parkinson??s Disease, Drugs & Aging, vol.13, issue.5, pp.381-390, 1998.
DOI : 10.2165/00002512-199813050-00004

M. Gottwald, J. Bainbridge, and G. Dowling, New Pharmacotherapy for Parkinson's Disease, Annals of Pharmacotherapy, vol.44, issue.10, pp.31-1205, 1997.
DOI : 10.1212/WNL.44.1.77

M. Ziegler, A. Castro-caldas, D. Signore, and S. , Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study, Movement Disorders, vol.18, issue.4, pp.418-425, 2003.
DOI : 10.1002/mds.10359

O. Rascol, D. Brooks, and A. Korczyn, A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa, New England Journal of Medicine, vol.342, issue.20
DOI : 10.1056/NEJM200005183422004

C. Stibe, A. Lees, and P. Kempster, SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS, The Lancet, vol.331, issue.8582, pp.403-406, 1988.
DOI : 10.1016/S0140-6736(88)91193-2

A. Destée, Troubles moteurs tardifs

C. Stefani, S. Drapier, and J. Peron, Continuous subcutaneous apomorphine infusion : an effective and cognitive well tolerated solution for untreatable motor fluctuations in patients with Parkinson's disease. Move disord, p.79, 2005.

T. Anne-charlotte, La maladie de Parkinson, aspects cliniques, physiopathologiques, étiologiques et thérapeutiques, Thèse de pharmacie, 1994.

Y. Ben-shlomo, Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry, BMJ, vol.316, issue.7139, pp.316-1191, 1998.
DOI : 10.1136/bmj.316.7139.1191

P. Rédaction, Sélégiline, avec 6 ans de recul : trop de risque dans la maladie de Parkinson, Revue Prescrire, issue.227, pp.22-251, 2002.

V. Myllylä, K. Sotaniemi, and J. Vüorinen, Selegiline as initial treatment in de novo parkinsonian patients, Neurology, vol.42, issue.2, pp.339-343, 1992.
DOI : 10.1212/WNL.42.2.339

L. Golbe, Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease, Neurology, vol.39, issue.8, pp.1109-1111, 1989.
DOI : 10.1212/WNL.39.8.1109

E. Clarke, Rasagiline for motor complications in Parkinson's disease. The Lancet, pp.914-916, 2005.

C. Geny, Les traitements de la maladie de Parkinson, un demi siècle de progrès. A.I.M, pp.10-13, 2007.

J. Nutt, Catéchol-O-méthyltransferase inhibition and the traitment of Parkinson's disease

A. Singh and S. Kulkarni, Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice, Methods and Findings in Experimental and Clinical Pharmacology, vol.24, issue.1, pp.23-32, 2002.
DOI : 10.1358/mf.2002.24.1.677124

D. Prada, M. Zürcher, G. Napolitano, and A. , Tolcapone inhibits both peripheral and central catechol-O-methyl transferase (COMT), Neurology, pp.45-252, 1995.

R. Schwab, A. England, and D. Poskanzer, Amantadine in the Treatment of Parkinson's Disease, JAMA: The Journal of the American Medical Association, vol.208, issue.7, pp.1168-1170, 1969.
DOI : 10.1001/jama.1969.03160070046011

O. Rascol, A five-year study of the incience of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa, N England J Med, issue.20, pp.342-1484, 2000.

O. Rascol and N. Fabre, Stratégie médicamenteuse initiale, pp.63-80, 1998.

C. Freydt and . La-maladie-de-parkinson-compliquée, Le médecin généraliste, p.2375, 2006.

F. Tison and I. Ghorayeb, Troubles associés dans la Maladie de Parkinson, Rev prat, vol.55, pp.744-746, 2005.

F. Durif and . Actualité-commentée, Quelles sont les indications chirurgicales dans la Maladie de Parkinson ? Le concours médical, pp.119-157, 1997.

M. Verin, Les indications dans la Maladie de Parkinson. La stimulation cérébrale profonde

K. L. Guiraudie, apport de la kinésithérapie dans la prise en charge globale des patients atteints de la Maladie de Parkinson, pp.19-21, 2006.

C. Geny, Les traitements de la maladie de Parkinson, un demi siècle de progrès, A.I.M, vol.126, pp.10-13, 2007.

V. E. De, Une thérapie cellulaire prometteuse dans le Parkinson. Le quotidien du médecin, 2008.

M. Kaplitt, Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial, The Lancet, vol.369, issue.9579, pp.369-2097, 2007.
DOI : 10.1016/S0140-6736(07)60982-9

. Outeiro, Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease, Science, vol.5837, pp.317-516, 2007.

T. Pritchard and K. Alloway, Neurosciences médicales. Les bases neuroanatomiques et neurophysiologiques.-1 e ed, pp.379-407, 2002.

D. Essai, The parkinson study Group "effect of Deprenyl on the progression of disability in early Parkinson's disease, N Engl J Med, issue.20, pp.321-1364, 1989.

. Le-cerveau-À-tous-les-niveaux, 79] Modèles animaux de la Maladie de Parkinson : http://psychologie.u-strasbg.fr/documentation/RGalani/TCC_modani_3.pdf [80] Rapport européen public d'évaluation (EPAR). DATSCAN. Résumé de l'Epar à l'intention du public, 2007.

. Collège-de-la-haute-autorité-de-santé, Guide-affection de longue durée : syndromes parkinsoniens dégénératifs ou secondaires non réversibles, 2007.

S. Canada, Médicaments et produits de santé Duodopa® : http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/conditions, p.102539